FOCELITE
HAPPY MINDS

WELBLU - Cure for Dengue Serotypes

Innovative Solution: Drug – Device Integrated Emerging Technology

Dengue : Challenges & Opportunity



141 countries affected by the most rapidly resulting in **36,000 fatalities**

A 30-fold increase in global incidence over the past 50 years – **No definitive treatment available** till date

The expected market value in 2023 - 2033 is - **$ 877.82 Million - $ 5435.25 Million**

Project : WELBLU Overview

Technology & Product Overview						
	Disease Category	Neglected Disease; On Priority list - **World Health Organization**				
	Segment	Public Health	Vector Borne	Viral Infection	Neglected Diseases	Emergency status
	Platform	**Emerging Technology**: Drug - Device				
	Regulatory Classification	**New Drug Application** - Fast Track Review				
	WELBLU	Repurposed Sublingual Drug formulation integrated with low wavelength visible light device				
	Action on Dengue Serotype	**Dual Action** :Disintegrate the Lipid Envelope & Modulate Host immune Cytokine Storm				
	Solutions	**Phase -1**	**Phase -2**			
		Treatment : Adult - Mild to Moderate	**Treatment** Children & Pediatric	**Adjuvant** : Pregnancy & Severity	**Biomarker Validation treatment** - Vulnerable for severity	**Treatment** for Coinfection & (metabolic) Comorbidity
	Proposed Dosage & Treatment duration	To be administered twice daily, in the morning and evening – 7 days + 3 days				
	Technology Validation	Safety & Efficacy Clinical Trial on COVID -19 Virus Completed		Dengue In-vitro Assay confirms inhibition of all 4 serotypes with a selective Index > 400		
	Health Risk	128 years Drug Existence		Low Risk of Developing Resistance		Dual Action
	Supply Chain	**Readiness:** Product Process validation completed and ready for commercial supply				

Process & Unmet Needs

Process & Expertise	**Team**	Board & C-CAMP	Advisory Panel	Operation Experts	Project Management	Partner Management
	Project Execution	**In-vitro & Animal (Completed)**	**Clinical (Completed)**	**Manufacturing& Regulatory (Completed)**	**Patent, Commercial & Legal (Completed)**	**Business Partnering (Completed)**
	Market Authorization Application – Regulatory Approval	**Preclinical** - Ready	**Chemistry Manufacturing & Control** - Ready	**Animal Studies** - In progress	**Pharmacokinetic, Efficacy & Safety - POC** - In progress	**Phase - 3 Partnering** (CSA & Industry)
	Market Access -Approval Route	India	World Health Organization		Others Market	
	Project Timelines	**Animal Studies** Oct 2024	**Clinical Trial Authorization** – Oct/ Nov 2024	**Pharmacokinetics** - Jan 2025	**POC - Efficacy & safety Studies** - June 2025 & Apply for Emergency Approval	**Phase – 3, Partnering** - Dec 2025 followed by commercialization
Market & Partnering	**Impact**	141 countries	105 million impacted	36,000 fatalities	30 X over 50 years	No definitive treatment available
	Market Potential	Market value of US$ 877.82 M in 2023 and is expected to accumulate a market value of US$ 5,435.25 M (CAGR 20%) forecast period 2023-33.				
	Indirect Competition	Currently **no approved Vaccine in India** and few other countries two vaccines with restricted usage approval. Tetravalent Vaccines under development: 3 - 4 years to enter market				
	Direct Competition	6 - 8 Players global in the development Pipelines with repurposed and NCE category - Single action strategy				

Our Journey

2017 -18

Formulation

Chemistry Manufacturing and Control

Technology platform

2019 - 2020

Core IP

Dosage

2019 - 20

Company formation

Mgmt team

Phase -1/2 POC Sars COV completed

Batch I manufacturing

2021 -22

Regulatory Meeting UK & Malaysia ,CDSCO Agency

Licensing for Manufacturing & CT- India

Revised Indication – Dengue

CMIE – AIIMS clinical Incubatee

C- CAMP Mentoring & Advisory

2023 -24

In-vitro Inhibition confirmed & Animal Model Studies in progress

WHO regulatory pathway – single for Phase -3 & product qualification

Regulatory Application Preparation

Clinical Trial preparation progress

Project Road map

Key Tasks	2019 -22			2023				2024				2025				2026			
	Q 1 & 2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Technology Development & POC																			
Dengue Invitro Studies																			
Animal Model & Clinical – Dose Titration Studies																			
Phase – 3 Trail																			
REGULATORY (Pre-Submission) & FILING																			
Planning and Launch																			
Ongoing Commercial Grade Production																			

Continue

About Us

Focelite is dedicated to revolutionizing value chain strategies and solutions by harnessing decades of diverse expertise and accelerating partnerships between industry and institutes.

With a laser focus on optimizing every aspect of the value chain, across viral infection Focelite is committed to delivering innovative solutions that drive dengue treatment.

01 Strategy & Solutions

New product strategy to capture widespread market attention

02 Product Innovation

Major partnership with industry leader to unlock opportunities

03 Transformation

Revenue growth surpassed market expectations

Board Members

Mr. Rajendra Bhandari Chairman

More than 3 decade of Experience on setting up Pharmaceutical operations and partnering from Greenfield for various dosage form

Vijay Kumar Ranka Managing Director

Molecular Biologist experienced from setting up complete research centre, specialized manufacturing catering to International market

Ms. Komal Minhas Strategic Partner

Microbiologist experienced in supply chain management , International Govt and NGO for product certification program, Trainer for Quality system

Dr. Vinayaka Srinivas CSO

Experienced developed cell biology technology platform & commercialization, Expertise in the development regulatory pathway of drug candidate

Dr. Praveen B Sancheti Clinical Advisor

More than 2 decade practise in surgery and managing Clinical drug programs. Expertise in infection management of pandemic in clinical setting

Mr. Rishav Saraf Financial Advisor

More than 2 decade of experience in auditing and compliance as per companies act . Expertise on in area of valuation

Our Mission

New cases of microbial infection and viral emergency are on the rise in diseases pose the greatest public health risk due to their epidemic potential and/or whether there is no or insufficient countermeasures.

At Focelite, with our research and development strategy teams, we develop anti - infective healthcare products, based on a multitarget approach enabled by the use of repurposed drugs in synergy with drug potential and benefitting from a high level of evidence of dual action.

Our goal: reduce the impact these diseases may have on millions of at-risk individuals, worldwide.

Focelite is a player committed to treatment, the spearhead of public health.

Thank You



Vijay Kumar Rank

info@focelite.com

www.welblu.com